益佰制药：目前已恢复小儿止咳糖浆的生产、销售

Core Viewpoint - Yibai Pharmaceutical (600594) announced the suspension of production and sales of its pediatric cough syrup due to a notice from the Guizhou Provincial Drug Administration, but has since resumed operations after rectification, with no significant impact expected on the company's performance [1] Group 1 - On August 2025, the company received a notice from the Guizhou Provincial Drug Administration to suspend production and sales of its pediatric cough syrup [1] - The company immediately halted production and sales upon receiving the notice [1] - After rectification, the company received a notice on September 16, 2025, lifting the suspension, allowing it to resume production and sales [1] Group 2 - The company anticipates that the suspension will not have a significant impact on its overall performance [1]